Homo sapiens met proto-oncogene (hepatocyte growth factor receptor) (MET), transcript variant 2
Synonyms:
AUTS9; c-Met; HGFR; RCCP2
Immunogen
A phospho specific peptide corresponding to residues surrounding tyrosine 1349 of human Met was used as an immunogen. This antibody detects Met phosphorylated at tyrosine 1349.
Buffer
50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
Clone Name
EP2367Y
Isotype
IgG
Species Reactivity
Human
Concentration
Purification
Guaranteed Application *
WB
Suggested Dilutions
WB (1:5000); IHC (1:50); ICC (1:50); IP (1:20)
Background
Met is a receptor protein-tyrosine kinase (RPTK) for hepatocyte growth factor (HGF), which is a multifunctional cytokine controlling cell growth, morphogenesis, and motility. Met overexpression has been identified in a variety of human cancers (1). Met kinase domain possesses unique features that distinguish met from other members of the src family of protein tyrosine kinases. These results also demonstrate that the product of the activated met gene is a fusion protein and that the amino terminal end of this fusion protein exhibits homology to laminin B1 (2). Data suggest that RanBP9, functioning as an adaptor protein for the Met tyrosine kinase domain, can augment the HGF-Met signaling pathway and that RanBP9 overexpression may cause constitutive activation of the Ras signaling pathway (2). Interaction of the hepatocyte growth factor (HGF) with its receptor, the Met tyrosine kinase, results in invasive growth, a genetic program essential to embryonic development and implicated in tumor metastasis. Met-mediated invasive growth requires autophosphorylation of the receptor on tyrosines located in the kinase activation loop (Tyr(1234)-Tyr(1235)) and in the tail (Tyr(1349)-Tyr(1356)).
Related Pathway
Adherens junction
Cytokine-cytokine receptor interaction
Focal Adhesion
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
